Pacira BioSciencesPCRX +1.48%75 EV-to-FCF is 9.11 as of Jul. 05, 2026, which is 69% below its 10-year median of 29.04. GuruFocus rates PCRX with a GF Score™ of 75/100 and a GF Value™ of $29.61 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 561 Drug Manufacturers companies, Pacira BioSciences ranks better than 80.39% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pacira BioSciences's Enterprise Value is $1,208.4 Mil.
Pacira BioSciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $132.7 Mil. Therefore, Pacira BioSciences's EV-to-FCF for today is 9.11.
The historical rank and industry rank for Pacira BioSciences's EV-to-FCF or its related term are showing as below:
PCRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -2115.35 Med: 29.04 Max: 315.07
Current: 9.11
During the past 13 years, the highest EV-to-FCF of Pacira BioSciences was 315.07. The lowest was -2115.35. And the median was 29.04.
PCRX's EV-to-FCF is ranked better than 80.39% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs PCRX: 9.11
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Pacira BioSciences's PE Ratio (TTM) for today is calculated as:
Pacira BioSciences's share price for today is $25.40.
Pacira BioSciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Pacira BioSciences EV-to-FCF Related Terms
Pacira BioSciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's EV-to-FCF falls into.
Pacira BioSciences's current Enterprise Value is $1,208.4 Mil.
Pacira BioSciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a EV-to-FCF of 9.11 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pacira BioSciences and its competitors. This is 69% below median its historical median of 29.04. According to the industry distribution chart, Pacira BioSciences ranks #110 out of 561 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Pacira BioSciences' EV-to-FCF too high?
Pacira BioSciences' current EV-to-FCF of 9.11 is 69% below median its 10-year median of 29.04. The Drug Manufacturers industry median EV-to-FCF is 20.85. Pacira BioSciences' value of 9.11 is 56.3% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #110 out of 561 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' EV-to-FCF compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #110 out of 561 companies for EV-to-FCF. This places Pacira BioSciences in the top 20% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.85. Pacira BioSciences' value of 9.11 is 56.3% below this benchmark. While the company's 10-year median is 29.04 vs. the industry median of 20.85, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current EV-to-FCF of 9.11 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current EV-to-FCF is 9.11, which is 69% below median its own 10-year median of 29.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.61, compared to a current price of $25.40 — trading 14.2% below its estimated fair value. The current EV-to-FCF is 9.11, which is 69% below median its 10-year median of 29.04 and 56.3% below the Drug Manufacturers industry median of 20.85. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current EV-to-FCF is 9.11 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $25.40 is trading 14.2% below its estimated GF Value™ of $29.61.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
EV-to-FCF: 9.11 (69% below median its 10-year median of 29.04)
GF Value™: $29.61 vs. price of $25.40 (14.2% below fair value)
Industry Position: 56.3% below the Drug Manufacturers median (#110 of 561)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for PCRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
